Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2020
Added 18,488 New Subscribers in 4Q20
4Q20 Revenues Increased by 19.2% YoY to RMB299.9 Million ($42.4 Million)
4Q20 Operating Income Increased by 68.1% YoY to RMB149.3 Million ($21.1 Million)
Non-GAAP Operating Income Up 58.7% YoY to RMB161.7 Million ($22.8 Million)
Conference Call to be Held on June 30, 2020 at 8:00 a.m. ET
HONG KONG, June 29, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the fourth quarter and full year of fiscal year 2020 ended March 31, 2020.
Fourth Quarter of Fiscal 2020 Highlights
-- Fourth quarter revenues increased by 19.2% year over year ("YoY") to
RMB299.9 million ($42.4 million).
-- New subscribers were 18,488, and the accumulated subscriber base
expanded to 833,094([1]).
-- Gross profit increased by 25.5% YoY to RMB256.4 million ($36.2 million).
Gross margin increased to 85.5% from 81.2% in the prior year period on
the back of a higher processing fee since April 2019.
-- Operating income increased by 68.1% YoY to RMB149.3 million ($21.1
million). Operating margin improved to 49.8% from 35.3% in the prior
year period, achieved mainly through higher gross profit and measures
taken to curb operating expenses.
-- Operating income before depreciation and amortization expense ("non-GAAP
operating income([2])") increased by 58.7% YoY to RMB161.7 million
($22.8 million).
-- Net income attributable to the Company's shareholders increased by 6.5%
YoY to RMB97.0 million ($13.7 million), after taking into account fair
value losses of equity securities and higher income tax expense.
-- Net cash provided by operating activities decreased by 59.4% YoY to
RMB90.0 million ($12.7 million) due to the impact from the 2019 novel
coronavirus ("COVID-19") pandemic, as it remained challenging to recruit
new subscribers.
Full Year Fiscal 2020 Highlights
-- Revenues increased by 23.8% YoY to RMB1,221.5 million ($172.5 million).
-- New subscriber sign-ups were 84,241 and the accumulated subscriber base
expanded to 833,094([1]).
-- Gross profit increased by 28.9% YoY to RMB1,032.3 million ($145.8
million).
-- Operating income increased by 46.5% to RMB559.0 million ($79.0 million).
-- Non-GAAP operating income([2]) improved by 40.2% to RMB608.5 million
($85.9 million).
-- Net income attributable to the Company's shareholders increased by 61.7%
YoY to RMB470.7 million ($66.5 million).
-- Net cash provided by operating activities was down by 21.2% YoY to
RMB624.0 million ($88.1 million).
"Despite the difficult market conditions resulting from the unprecedented COVID-19 pandemic and a continued decrease in newborn numbers in the markets in which we operate, we managed to recruit over 84,000 new subscribers during fiscal 2020 and achieved our full-year target," said Ms. Ting Zheng, Chairperson and Chief Executive Officer of GCBC. "As the impact of COVID-19 lingers, hospitals in China have implemented strict access rules, and consumers remain cautious on inter-personal contact and discretionary spending. In addition, the regulatory uncertainties of the cord blood banking industry in China continue to exist. Therefore, we believe that the business environment for the next fiscal year will remain challenging. However, we will continue to execute on our strategy to overcome the short-term challenges, focus on achieving operational targets, and explore business opportunities to pave a solid path for our long-term development."
Summary - Fourth
Q
uarter and Full
Y
ear Ended March 31, 2019 and 2020
Three Months Ended March 31,
Year Ended March 31,
2019 2020 2019 2020
(In thousands)
RMB
RMB
US$ RMB RMB
US$
Revenues 251,651 299,888 42,352 986,754 1,221,460 172,503
Gross Profit 204,276 256,430 36,215 800,727 1,032,332 145,793
Operating Income[3] 88,854 149,339 21,091 381,657 559,033 78,950
Change in Fair Value
of Equity Securities 11,526 (24,155) (3,411) (57,125) (13,172) (1,860)
Net Income Attributable
to the Company's
Shareholders 91,108 97,007 13,701 291,124 470,717 66,477
Earnings per Share
- Basic (RMB/US$) 0.74 0.80 0.11 2.40 3.87 0.55
- Diluted (RMB/US$) 0.74 0.80 0.11 2.40 3.87 0.55
Revenues
Breakdown (%)
Processing Fees
and Other Services 59.1% 61.1% 60.9% 63.0%
Storage Fees 40.9% 38.9% 39.1% 37.0%
New Subscribers
(persons) 22,194 18,488 89,366 84,241
Total Accumulated
Subscribers
(persons) 750,273
833,094[1] 750,273 833,094[1]
Summary - Selected Cash Flow Statement Items
Three Months Ended March 31, Year
Ended March 31,
2019 2020 2019 2020
(In thousands) RMB RMB US$ RMB RMB US$
Net cash provided by 221,495 89,962 12,704 792,118 624,004 88,124
operating activities
Net cash used in (508) (1,026) (144) (30,210) (146,061) (20,626)
investing activities
Net cash used in (3,019) (21,192) (4,039) (570)
financing activities
Fourth Quarter of Fiscal 2020 Financial Results
REVENUES. Revenues in the fourth quarter of fiscal 2020 increased by 19.2% YoY to RMB299.9 million ($42.4 million). The growth was mainly driven by the implementation of a new processing fee in April 2019 as well as the expansion of the total subscriber base.
During the reporting quarter, despite the COVID-19 pandemic affecting the Company's operations, 18,488 new subscribers were recruited. Revenues generated from processing fees and other services in the fourth quarter increased by 23.3% YoY to RMB183.4 million ($25.9 million). As a percentage of revenues, revenues generated from processing fees and other services accounted for 61.1% compared to 59.1% in the prior year period.
The Company's accumulated subscriber base reached 833,094([1]) by the end of March 2020, and revenues generated from storage fees increased by 13.1% YoY to RMB116.5 million ($16.5 million). Storage fees revenues accounted for 38.9% of the total revenues, down from 40.9% in the prior year period.
GROSS PROFIT. Gross profit for the fourth quarter of fiscal 2020 increased by 25.5% YoY to RMB256.4 million ($36.2 million). As a result of the boosting effect from the new processing fee, gross margin expanded to 85.5% from 81.2% in the prior year period.
OPERATING INCOME and NON-GAAP OPEARTING INCOME([2]). Fourth quarter operating income increased by 68.1% YoY to RMB149.3 million ($21.1 million) as a result of increased gross profit and the implementation of cost saving measures. Depreciation and amortization expenses for the reporting quarter was RMB12.4 million ($1.8 million) compared to RMB13.1 million in prior year period. Fourth quarter non-GAAP operating income([2]) improved by 58.7% YoY to RMB161.7 million ($22.8 million). Non-GAAP operating margin improved to 53.9% from 40.5% in the prior year period.
Research and Development Expenses. Research and development expenses for the fourth quarter amounted to RMB3.6 million ($0.5 million), representing a 22.2% decline YoY.
Sales and Marketing Expenses. Sales and marketing expenses for the fourth quarter was down by 10.1% YoY to RMB60.5 million ($8.5 million). The decrease was mainly driven by a decrease in staff and performance-related costs as well as a halt to non-essential marketing and promotional activities due to the COVID-19 pandemic. As a percentage of revenues, sales and marketing expenses decreased from 26.7% in the prior year period to 20.2% in the reporting period.
General and Administrative Expenses. General and administrative expenses for the fourth quarter decreased to RMB43.0 million ($6.1 million) from RMB43.5 million in the prior year period and from RMB47.9 million in the prior quarter, the net effect of which was mainly driven by reductions in costs for staff and provisions. General and administrative expenses as a percentage of revenues decreased to 14.3% from 17.3% from the prior year period.
OTHER INCOME AND EXPENSES.
Change in Fair Value of Equity Securities. In the reporting quarter, the Company recognized a decrease in fair value of equity securities, or "mark-to-market losses," of RMB24.2 million ($3.4 million) compared to mark-to-market gains of RMB11.5 million in the prior year period. The changes were mainly attributable to the valuation of the Company's investments in equity securities.
NET INCOME ATTRIBUTABLE TO THE COMPANY'S SHAREHOLDERS. As a result of the increase in operating income, netted by a decrease in fair value of equity securities and an increase in income tax expense, net income attributable to the Company's shareholders for the reporting period increased by 6.5% YoY to RMB97.0 million ($13.7 million). Net margin for the fourth quarter of fiscal 2020 was 32.3%.
EARNINGS PER SHARE. Basic and diluted earnings per ordinary share for the fourth quarter of fiscal 2020 improved to RMB0.80 ($0.11).
Full Year Fiscal 2020 Financial Results
For the full year fiscal 2020, total revenues increased by 23.8% YoY to RMB1,221.5 million ($172.5 million). The increase was mainly attributable to the application of a new processing fee as well as growth in storage fee revenues. Revenues from processing fees and other services increased by 28.1% YoY to RMB769.8 million ($108.7 million), and revenues from storage fees increased by 17.1% YoY to RMB451.7 million ($63.8 million). Gross profit increased by 28.9% YoY to RMB1,032.3 million ($145.8 million). Operating income increased by 46.5% YoY to RMB559.0 million ($79.0 million). Non-GAAP operating income([2]) improved by 40.2% YoY to RMB608.5 million ($85.9 million). Net income attributable to the Company's shareholders increased by 61.7% to RMB470.7 million ($66.5 million). Basic and diluted earnings per ordinary share increased to RMB3.87 ($0.55). Net cash provided by operating activities in the full year of fiscal 2020 was RMB624.0 million ($88.1 million) compared to RMB792.1 million in the prior year.
Recent Developments
-- On June 4, 2019, the board of directors of the Company (the "Board")
received a non-binding proposal letter from Cordlife Group Limited
("Cordlife"), a company listed on the Mainboard of the Singapore
Exchange Securities Trading Limited ("SGX"), pursuant to which Cordlife
proposed to combine the businesses of Cordlife and the Company, by way
of a statutory merger. According to the letter, Cordlife would issue
approximately 2,497.9 million ordinary shares at an issue price of
SGD0.5 per ordinary share in exchange for all of the outstanding
ordinary shares of the Company at $7.50 per ordinary share. Upon
completion of the proposed transaction, the Company's ordinary shares
would be delisted from the New York Stock Exchange, and Cordlife
ordinary shares would continue to trade on the SGX. On June 5, 2019, the
Board formed a special committee of independent directors (the "Special
Committee") who are not affiliated with Cordlife to evaluate such
proposal. On November 11, 2019, the Company appointed Mr. Jack Chow as
an independent non-executive director ("INED") of the Board. Mr. Chow
has extensive professional experience and a broad network in the finance
and investment industry. He replaced Mr. Mark Chen as a member of the
Audit Committee and Ms. Jennifer Weng as a member of the Special
Committee. Mr. Chow also joined the Board's Compensation Committee and
Nominating and Corporate Governance Committee. On February 6, 2020, the
Company appointed Mr. Jacky Cheng as an INED of the Board. Mr. Cheng has
extensive professional experience and knowledge in legal and compliance
and Chinese laws. He joined the Board's Compensation Committee as a
member and the Company's Special Committee as a member. Currently, the
Special Committee is composed of four members, including Mr. Mark Chen,
Dr. Ken Lu, Mr. Jack Chow, and Mr. Jacky Cheng.
-- The Company cautions its shareholders and others considering trading its
ordinary shares that no decisions have been made with respect to the
Company's response to the proposed transaction with Cordlife. The
proposed transaction is still subject to various conditions, including
but not limited to, completion of due diligence, parties entering into a
definitive agreement, and/or each of Cordlife and the Company obtaining
its relevant regulatory and shareholder approvals. In addition,
litigation has been filed in the Cayman Islands challenging the proposed
transaction. There can be no assurance that any definitive offer will be
made, that any agreement will be executed, or that this or any other
transaction will be approved or consummated.
Error occurred while generating ASCII Content for table
Conference Call
The Company will host a conference call at 8:00 a.m. ET on Tuesday, June 30, 2020, to discuss its financial performance and give a brief overview of the Company's recent developments followed by a question and answer session. Interested parties can access the audio webcast through the Company's IR website at http://ir.globalcordbloodcorp.com. A replay of the webcast will be accessible two hours after the conference call and available for seven days at the same URL link above. Listeners can also access the call by dialing 1-646-722-4977 or 1-855-824-5644 for US callers, or +852-3027-6500 for Hong Kong callers, access code: 50605287#.
Use of Non-GAAP Financial Measures
GAAP results for the three months and year ended March 31, 2020, include non-cash items related to depreciation and amortization expenses. To supplement the Company's unaudited condensed consolidated financial statements presented on a U.S. GAAP basis, the Company has provided adjusted financial information excluding the impact of these items in this press release. The non-GAAP financial measure represents non-GAAP operating income. Such adjustment is a departure of U.S. GAAP; however, the Company's management believes that these adjusted measures provide investors with a better understanding of how the results relate to the Company's historical performance. Also, management uses non-GAAP operating income as a measurement tool for evaluating actual operating performance compared to budget and prior periods. These adjusted measures should not be considered an alternative to operating income, or any other measure of financial performance or liquidity presented in accordance with U.S. GAAP. These measures are not necessarily comparable to a similarly titled measure of another company. A reconciliation of the adjustments to U.S. GAAP results appears in exhibit 3 accompanying this press release. This additional adjusted information is not meant to be considered in isolation or as a substitute for U.S. GAAP financials. The adjusted financial information that the Company provides also may differ from the adjusted information provided by other companies.
About Global Cord Blood Corporation
Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. For more information, please visit the Company's website at: http://www.globalcordbloodcorp.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or the Company's future financial performance. The Company has attempted to identify forward-looking statements by terminology including "anticipates", "believes", "expects", "can", "continue", "could", "estimates", "intends", "may", "plans", "potential", "predict", "should" or "will" or the negative of these terms or other comparable terminology. These statements are only predictions, uncertainties and other factors may cause the Company's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this press release is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company expectations are as of the date this press release is issued, and the Company does not intend to update any of the forward-looking statements after the date this press release is issued to conform these statements to actual results, unless required by law.
The forward-looking statements included in this press release are subject to risks, uncertainties and assumptions about the Company's businesses and business environments. These statements reflect the Company's current views with respect to future events and are not a guarantee of future performance. Actual results of the Company's operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: the effects of the current COVID-19 outbreak, including the inability of the Company's salesforce to return to work due to current lockdowns implemented in various cities in the PRC and the imposition by some hospitals in the PRC of restrictions on entrance to solely to hospital staff and patients; levels of consumer confidence in the healthcare services sector generally in the PRC as a result of the outbreak; the length of the COVID-19 outbreak and severity of such outbreak across the globe; the pace of recovery following the COVID-19 outbreak; continued compliance with government regulations regarding cord blood banking in the People's Republic of China, or PRC and any other jurisdiction in which the Company conducts its operations; changing legislation or regulatory environments in the PRC and any other jurisdiction in which the Company conducts its operations; the acceptance by subscribers of the Company's different pricing and payment options and reaction to the introduction of the Company's premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; the existence of a significant shareholder able to influence and direct the corporate policies of the Company; credit risks affecting the Company's revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company's ability to effectively manage its growth, including maintaining effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of legislative developments in the U.S. affecting listed issuers whose independent registered public accounting firms are based in China and not subject to U.S. Public Company Accounting Oversight Board inspections, international pressure on trade and currency against the PRC and its potential impact on the PRC consumer behavior, as well as general economic conditions; the non-binding proposal letter from Cordlife and the potential transaction contemplated by such letter, and other relevant risks detailed in the Company's filings with the Securities and Exchange Commission in the United States.
This announcement contains translations of certain Renminbi amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from Renminbi to U.S. dollars as of and for the periods ended March 31, 2020 were made at the noon buying rate of RMB7.0808 to $1.00 on March 31, 2020 in the City of New York for cable transfers in Renminbi per U.S. dollar as certified for customs purposes by the Federal Reserve Bank of New York. Global Cord Blood Corporation makes no representation that the Renminbi or U.S. dollar amounts referred to in this press release could have been or could be converted into U.S. dollars or Renminbi, at any particular rate or at all.
For more information, please contact:
Global Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@globalcordbloodcorp.com
ICR, Inc.
Mr. William Zima
Tel: (+86) 10-6583-7511
U.S. Tel: (646) 405-5185
Email: william.zima@icrinc.com
EXHIBIT 1
GLOBAL CORD BLOOD CORPORATION
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
As of March 31, 2019 and 2020
---
March 31, March 31,
2019 2020
RMB
RMB
US$
(in thousands except share data)
ASSETS
Current assets
Cash and cash equivalents 4,997,861 5,473,373 772,988
Accounts receivable, less allowance for
doubtful accounts
(March 31, 2019: RMB89,634;
March 31, 2020: RMB111,869 (US$15,799)) 96,923 104,251 14,723
Inventories 27,612 43,758 6,180
Prepaid expenses and other receivables 25,532 44,785 6,325
Total current assets 5,147,928 5,666,167 800,216
Property, plant and equipment, net 545,340 522,679 73,817
Operating lease right-of-use assets[4] 4,548 642
Non-current deposits 236,719 347,360 49,057
Non-current accounts receivable, less
allowance for doubtful accounts
(March 31, 2019: RMB74,800;
March 31, 2020: RMB71,421 (US$10,087)) 104,857 160,031 22,600
Inventories 77,194 85,109 12,020
Intangible assets, net 97,444 92,823 13,109
Investment in equity securities at fair value 107,362 101,306 14,307
Other equity investment 189,129 189,129 26,710
Deferred tax assets 44,981 50,701 7,160
Total assets 6,550,954 7,219,853 1,019,638
LIABILITIES
Current liabilities
Accounts payable 33,566 19,992 2,823
Accrued expenses and other payables 79,977 113,989 16,099
Operating lease liabilities[4] 1,717 242
Deferred revenue 461,986 402,751 56,879
Income tax payable 20,113 32,329 4,566
Total current liabilities 595,642 570,778 80,609
Non-current deferred revenue 2,108,442 2,289,762 323,376
Non-current operating lease liabilities[4] 1,782 252
Other non-current liabilities 404,482 450,900 63,679
Deferred tax liabilities 19,626 18,140 2,562
Total liabilities 3,128,192 3,331,362 470,478
EQUITY
Shareholders' equity of Global Cord Blood Corporation
Ordinary shares
US$0.0001 par value, 250,000,000 shares authorized,
121,687,974 and 121,551,075 shares issued and outstanding
as of March 31, 2019 and 2020, respectively 83 83 12
Additional paid-in capital 2,101,582 2,101,582 296,801
Treasury stock, at cost (March 31, 2019 and 2020: 136,899
shares, respectively) (2,815) (2,815) (398)
Accumulated other comprehensive losses (88,738) (94,663) (13,369)
Retained earnings 1,407,223 1,877,940 265,215
Total equity attributable to Global Cord Blood 3,417,335 3,882,127 548,261
Corporation
Non
-
controlling interests 5,427 6,364 899
Total equity 3,422,762 3,888,491 549,160
Total liabilities and equity 6,550,954 7,219,853 1,019,638
[4]
Since April 1, 2019, the Company adopted Accounting Standards Update Topic 842 using a modified retrospective transition approach which resulted in the recognition of right-of-use assets and lease liabilities for
operating leases as of April 1, 2019 of approximately RMB6.9 million and RMB5.8 million, respectively.
EXHIBIT 2
GLOBAL CORD BLOOD CORPORATION
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
For the Three Months and Year Ended March 31, 2019 and 2020
---
Three months ended March 31, Year
ended March 31,
2019 2020 2019 2020
RMB RMB US$ RMB
RMB US$
(in thousands except per share data)
Revenues 251,651 299,888 42,352 986,754 1,221,460 172,503
Direct costs (47,375) (43,458) (6,137) (186,027) (189,128) (26,710)
Gross profit 204,276 256,430 36,215 800,727 1,032,332 145,793
Operating expenses
Research and
development (4,635) (3,605) (509) (14,688) (21,109) (2,981)
Sales and marketing (67,301) (60,505) (8,545) (235,062) (261,958) (36,996)
General and
administrative (43,486) (42,981) (6,070) (169,320) (190,232) (26,866)
Total operating
expenses (115,422) (107,091) (15,124) (419,070) (473,299) (66,843)
Operating income 88,854 149,339 21,091 381,657 559,033 78,950
Other income/
(expenses), net
Interest income 6,049 6,287 888 25,320 25,359 3,581
Foreign currency
exchange gains/
(losses) 15 (139) (20) (62) (303) (43)
Change in fair value of
equity securities 11,526 (24,155) (3,411) (57,125) (13,172) (1,860)
Dividend income 976 507 72
Others 2,711 2,111 298 5,695 7,388 1,043
Total other income/
(expenses), net 20,301 (15,896) (2,245) (25,196) 19,779 2,793
Income before
income tax 109,155 133,443 18,846 356,461 578,812 81,743
Income tax expense (16,405) (33,877) (4,784) (61,260) (101,084) (14,276)
Net income 92,750 99,566 14,062 295,201 477,728 67,467
Net income attributable
to non-controlling
interests (1,642) (2,559) (361) (4,077) (7,011) (990)
Net income
attributable to
Global Cord Blood
Corporation's
shareholders 91,108 97,007 13,701 291,124 470,717 66,477
Earnings per share
Attributable to
ordinary shares
- Basic 0.74 0.80 0.11 2.40 3.87 0.55
- Diluted 0.74 0.80 0.11 2.40 3.87 0.55
Other comprehensive
(losses)/income, net
of nil income taxes
- Foreign
currency
translation
adjustments (10,073) 1,875 265 28,232 (5,925) (837)
Comprehensive
income 82,677 101,441 14,327 323,433 471,803 66,630
Comprehensive
income attributable
to non-controlling
interests (1,642) (2,559) (361) (4,077) (7,011) (990)
Comprehensive
income attributable
to Global Cord
Blood Corporation's
shareholders 81,035 98,882 13,966 319,356 464,792 65,640
EXHIBIT 3
GLOBAL CORD BLOOD CORPORATION
RECONCILIATION OF NON-GAAP OPERATING INCOME
For the Three Months and Year Ended March 31, 2019 and 2020
---
Three months ended March 31, Year ended March 31,
2019 2020 2019 2020
RMB RMB US$ RMB RMB US$
(in thousands)
GAAP amount of
operating income 88,854 149,339 21,091 381,657 559,033 78,950
Depreciation and
amortization
expenses[5] 13,091 12,409 1,752 52,365 49,449 6,984
Non-GAAP
operating income 101,945 161,748 22,843 434,022 608,482 85,934
[5]
Depreciation and amortization expenses relate to property, plant and equipment and intangible assets, respectively.
View original content:http://www.prnewswire.com/news-releases/global-cord-blood-corporation-reports-financial-results-for-the-fourth-quarter-and-full-year-of-fiscal-2020-301084919.html
SOURCE Global Cord Blood Corporation
